| Revenue growth | Flat YoY at consolidated level; high subsidiary growth offset standalone decline. |
|---|---|
| Margins | EBITDA margins expanded significantly; Innoxel turned EBITDA positive in Q4. |
| Order book | ₹171cr for BPL standalone providing FY27 visibility. |
| Demand visibility | Strong; order book at ₹171cr for standalone business. |
| Management confidence | High confidence in FY27 guidance after finishing investment phase. |
Growth
FY26 Consolidated Revenue: ₹345.4cr (+1.6% YoY); EBITDA: ₹15.8cr (+485% YoY). Innoxel grew 174% to ₹72.4cr.
Outlook
FY27 Guidance: Standalone growth 10-15%; Innoxel 35-45%; Varenyam 20-25%. Peak revenue targets ₹400-500cr by 2030.
Risks
Soft standalone exports due to deferred tenders; geopolitical disturbances causing 3-month project delays; near-term disruption from audits.
Earnings Call filed with BSE, BSE: 541096. Summary written with AI assistance from the document.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,895.10
- Market cap
- ₹1,306 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- -84.8×Sector 50.4×
- Promoter holding
- 67.20%+0.03% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Board Meeting Date
Bharat Parenterals intimated that its Board will meet on 29 September 2026 to consider a preferential equity issue. The agenda item is proposed, not yet approved, with no amount disclosed.
Bharat Parenterals Management Change
Bharat Parenterals Limited has re-appointed Mr. Hemang Jayendrabhai Shah as Executive Director for a 5-year term effective July 2, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited held its 33rd Annual General Meeting on September 19, 2026. The proceedings covered the adoption of financial statements and various resolutions.
Bharat Parenterals Investor Presentation: Key Takeaways
Q1 FY27 consolidated revenue fell 19% YoY to ₹93.7 Cr due to standalone institutional order base effects. Gross margins expanded 1,000bps to 50.6%, though consolidated PAT remained negative at ₹(3.6) Cr.
- Call
- Guides 25% growth
Bharat Parenterals Q1 FY27 Results: Net Loss of ₹3.6 Cr, Loss Widens
Bharat Parenterals Ltd reported revenue from operations of ₹93.7 Cr (-19.2% YoY) and a net loss of ₹3.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹3.6 Cr
Bharat Parenterals Earnings Call: Key Takeaways
Bharat Parenterals calls FY26 a 'bridge year' of transition, clearing regulatory hurdles and scaling subsidiaries despite flat consolidated revenue of ₹345.4 cr. Growth in high-margin subsidiaries Inoxxel and Verineum offset a 23% decline in standalone exports.